论文部分内容阅读
目的探讨伊托必利联合复方阿嗪米特对功能性消化不良患者胃容受性及症状的影响。方法选择2011年3月—2014年5月收治的功能性消化不良患者106例,随机分为对照组和联合组各53例。对照组仅采用伊托必利治疗,联合组采用伊托必利联合复方阿嗪米特治疗,比较两组患者治疗前后临床症状评分、胃容受性、胃排空率的变化情况及临床疗效。计量资料采用配对t检验,计数资料采用χ2检验,P<0.05为差异有统计学意义。结果治疗后,对照组餐后饱胀、早饱积分分别为(1.9±0.4)、(2.0±0.3)分,联合组分别为(1.2±0.2)、(1.3±0.2)分,两组比较差异均有统计学意义(均P<0.05)。治疗后,对照组胃容受性为(351.2±43.2)ml,联合组为(385.1±46.5)ml,两组比较差异有统计学意义(P<0.05)。治疗后,对照组餐后2、5 h胃排空率分别为45.3%、75.5%,联合组分别为67.9%、98.1%,两组比较差异均有统计学意义(均P<0.05)。对照组总有效率为54.7%,联合组为84.9%,两组比较差异有统计学意义(P<0.05)。结论伊托必利联合复方阿嗪米特肠溶片能明显降低功能性消化不良患者的临床症状,缩短胃排空时间,提高胃容受性,提高治疗效果,其效果优于单用伊托必利,值得临床推广。
Objective To investigate the effects of itopride combined with compound azamethin on gastric tolerance and symptoms in patients with functional dyspepsia. Methods 106 patients with functional dyspepsia admitted from March 2011 to May 2014 were randomly divided into control group and combination group of 53 cases. The control group was treated with itopride only. The combination group was treated with itopril combined with compound azinamazole. The changes of clinical symptom scores, gastric receptivity, gastric emptying rate and clinical efficacy before and after treatment were compared between the two groups . Measurement data using paired t test, count data using χ2 test, P <0.05 for the difference was statistically significant. Results After treatment, the fullness and fullness of postprandial fullness in the control group were (1.9 ± 0.4) and (2.0 ± 0.3) points, respectively, and those in the control group were (1.2 ± 0.2) and (1.3 ± 0.2) All were statistically significant (P <0.05). After treatment, the gastric tolerance of the control group was (351.2 ± 43.2) ml and that of the combined group was (385.1 ± 46.5) ml, with significant difference between the two groups (P <0.05). After treatment, the rate of gastric emptying at 2 and 5 h after meal in the control group was 45.3% and 75.5% respectively, and the combined group was 67.9% and 98.1% respectively. There was significant difference between the two groups (all P <0.05). The total effective rate was 54.7% in the control group and 84.9% in the combined group, with significant difference between the two groups (P <0.05). Conclusion Itopride combined with compound azinamid enteric-coated tablets can significantly reduce the clinical symptoms of patients with functional dyspepsia, shorten the gastric emptying time, improve gastric tolerance and improve the therapeutic effect, the effect is better than the single use of ito Will benefit, it is worth clinical promotion.